Mustang’s CAR-T MB-106 Shows Potential Competitiveness In CD20 Space
The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.
You may also be interested in...
Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio
Roche has gained approval for the first of its two bispecific therapies for lymphoma, but will face stiff competition from Genmab and AbbVie’s late-stage rival.
EU Approval Decision Imminent For First CD20xCD3 Bispecific Antibody
If Roche gets the nod from the European Medicines Agency for mosunetuzumab this week, it could become the first company to market a CD20xCD3 bispecific antibody for follicular lymphoma.
Roche Seeks Speedy EU Review For Second Bispecific Antibody
The European Medicines Agency was this week deciding whether to grant accelerated assessment for glofitamab.